Pvs230D1-EPA/Matrix-M / National Institute of Allergy and Infectious Diseases - LARVOL DELTA

Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults (clinicaltrials.gov) - P1 | N=105 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed | Trial completion date: Apr 2026 ➔ Nov 2025 | Trial primary completion date: Apr 2026 ➔ Nov 2025

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Malaria

Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults (clinicaltrials.gov) - P1 | N=105 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Nov 2025 ➔ Apr 2026 | Trial primary completion date: Nov 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Infectious Disease • Malaria

Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults (clinicaltrials.gov) - P1 | N=105 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | N=59 ➔ 105

Enrollment change • Infectious Disease • Malaria

Pvs230D1-EPA/Matrix-M™: Initial phase 1 trial results of a Plasmodium vivax transmission blocking vaccine (ASTMH 2024) - "The vaccine has induced high levels of anti-Pvs230D1 antibodies at initial timepoints and immunogenicity studies are ongoing. Further exploratory studies, including assessments of functional activity in mosquito feeding assays, are planned and results will be provided as available."

Late-breaking abstract • P1 data • Infectious Disease • Malaria

Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults (clinicaltrials.gov) - P1 | N=59 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting | N=200 ➔ 59 | Trial completion date: May 2025 ➔ Nov 2025 | Trial primary completion date: May 2025 ➔ Nov 2025

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Malaria

Phase 1 trial design for Pvs230D-EPA/Matrix MTM, a novel transmission blocking vaccine for malaria caused by Plasmodium vivax (ASTMH 2023) - "Pvs230D1-EPA/Matrix-M is the first P. vivax TBV based on the gamete surface protein, Pvs230...Subjects will be followed for one year after the final vaccination to assess for potential immune-mediated medical conditions. Confirmation of safety in healthy malaria naive adults will permit rapid progression to safety and efficacy studies in malaria endemic regions."

Late-breaking abstract • P1 data • Infectious Disease • Malaria

Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2024 ➔ May 2025 | Trial primary completion date: Aug 2024 ➔ May 2025

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Malaria

Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults (clinicaltrials.gov) - P1 | N=200 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

New P1 trial • Infectious Disease • Malaria